Quasar Bio-Tech, Inc

Form 483 issued December 20, 2024 · Yorba Linda, California

Inspection
Dec 16 – Dec 20, 2024
Observations
4
Pages
5
FEI number
3006182559

In short: On December 20, 2024, FDA issued a Form 483 with 4 observations to Quasar Bio-Tech, Inc in Yorba Linda, California (FEI 3006182559) after an inspection that ran Dec 16 – Dec 20, 2024. The investigators were Jae H. Lee and Marlo-Ian M. Alintanahin. Most observations concern management controls and production & process controls.

At a glance

Observations span 4 systems, led by management controls.

Management controls1
Production & process controls1
CAPA1
Records & documents1

What FDA observed

Preview: the opening words of each observation
  1. 01

    Quality audits were not performed at defined intervals to determine whether the quality system activities and…

  2. 02

    There is no agreement with suppliers to notify you of changes in…

  3. 03

    Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have…

  4. 04

    Document control procedures have…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Quasar Bio-Tech, Inc?

FDA listed 4 observations on this Form 483, mostly about management controls, production & process controls and cAPA. The opening words of each observation are shown on this page.

Who inspected Quasar Bio-Tech, Inc?

Jae H. Lee and Marlo-Ian M. Alintanahin are named on this Form 483, for the inspection of Dec 16 – Dec 20, 2024. Each investigator has a profile showing what they cite most.

When was Quasar Bio-Tech, Inc inspected by FDA?

The inspection ran Dec 16 – Dec 20, 2024, and the Form 483 is dated December 20, 2024.

How do I get the full Form 483 for Quasar Bio-Tech, Inc?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free